Viablife

Viablife is a biotechnology company based in Hangzhou, China, specializing in safe and environmentally friendly chemical raw materials aimed at the beauty and personal care sectors. Founded in 2015 in Hangzhou, China, Viablife focuses on providing high-performance chemical raw materials for beauty and personal care. The company has engaged in a total of 8 deals, with its most recent funding round occurring on May 20, 2025. Viablife was established to address the growing demand for innovative solutions in health and personal care sectors.

Hangzhou Weibo Lai Biotechnology Co. , Ltd. specializes in high-performance, safe, and environmentally friendly chemical raw materials tailored for the beauty and personal care sectors, including skincare, haircare, and personal hygiene products. The company focuses on addressing diverse skin conditions with its innovative solutions, emphasizing quality and safety.

In addition to personal care, Weibo Lai offers bio-pharmaceuticals characterized by stable quality and high biocompatibility, catering to the health sector with products aimed at enhancing human well-being. The company is also a supplier of premium raw materials for health foods, beverages, and dietary supplements, working closely with clients to develop customized solutions that promote a sustainable future. Furthermore, Weibo Lai is committed to advancing the bio-based materials industry by providing top-quality bio-based products, contributing to the reformation of green industrial practices. The revenue model of Hangzhou Weibo Lai Biotechnology Co.

, Ltd. is structured around B2B transactions, where the company engages directly with manufacturers and suppliers in the beauty, health, and food sectors. Clients typically enter into partnerships or supply agreements, allowing for consistent delivery of their specialty products. These transactions often involve bulk orders of proprietary formulations and raw materials that support product development for client brands.

Specific pricing structures are tailored to the needs of the clients, reflecting the quality and innovation embedded in Weibo Lai's offerings. Signature products, particularly those related to bio-pharmaceuticals and bio-based materials, are central to the company’s revenue generation, aligning with current market demands for safe and effective solutions in various industries. In May 2025, Viablife raised an undisclosed amount of venture funding from new investor Huaxia Hengtian Asset Management. The company plans to expand its product portfolio, including new launches focused on bio-pharmaceuticals and sustainable materials, expected by late 2025.

Additionally, Viablife aims to penetrate new markets, particularly in Southeast Asia and Europe, by 2026, leveraging the recent funding to enhance product development and market outreach.